---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000183"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:59:43.453066+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M

## Summary
- Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).
- Net loss $15.7M ($0.11 EPS); excludes CEO succession restructuring costs of $6.1M gives adjusted EPS ($0.06).
- FY 2024 total net revenue guidance raised to $198-202M from prior $190-200M; year-end cash guided to $68-72M.
- Cash, cash equivalents and short-term investments $69.4M at Sept 30, 2024.
- 12th consecutive quarter of product revenue growth >20%; Recorlev patient count +125% YoY.

## SEC filing metadata
- accession: 0001867096-24-000183
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000183/0001867096-24-000183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000183/xers-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000183
- JSON: https://secwatch.observer/filing/0001867096-24-000183.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.